CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
CervoMed (NASDAQ:CRVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)